A price for cost-effectiveness: Implications for recombinant human activated protein C (rhAPC)

被引：7

作者：

Chalfin, DB ^{[1
]}

Teres, D

Rapoport, J

机构：

[1] Maimonides Hosp, Brooklyn, NY 11219 USA

[2] Albert Einstein Coll Med, New York, NY USA

[3] Tufts Univ, Sch Med, Medford, MA 02155 USA

[4] Mt Holyoke Coll, S Hadley, MA 01075 USA

来源：

CRITICAL CARE MEDICINE | 2003年 / 31卷 / 01期

关键词：

D O I：

10.1097/00003246-200301000-00049

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：306 / 308

页数：3

共 14 条

[1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
Angus, DC
Linde-Zwirble, WT
Lidicker, J
Clermont, G
Carcillo, J
Pinsky, MR
[J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
[2] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
Angus, DC
Linde-Zwirble, WT
Clermont, G
Ball, DE
Basson, BR
Ely, EW
Laterre, PF
Vincent, JL
Bernard, G
van Hout, B
[J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
[3] Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard, GR
Vincent, JL
Laterre, P
LaRosa, SP
Dhainaut, JF
Lopez-Rodriguez, A
Steingrub, JS
Garber, GE
Helterbrand, JD
Ely, EW
Fisher, CJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
[4] THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDY DESIGN BASED ON SURVIVAL ANALYSIS
KNAUS, WA
HARRELL, FE
FISHER, CJ
WAGNER, DP
OPAL, SM
SADOFF, JC
DRAPER, EA
WALAWANDER, CA
CONBOY, K
GRASELA, TH
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (10): : 1233 - 1241
[5] CUSTOMIZED PROBABILITY-MODELS FOR EARLY SEVERE SEPSIS IN ADULT INTENSIVE-CARE PATIENTS
LEGALL, JR
LEMESHOW, S
LELEU, G
KLAR, J
HUILLARD, J
RUE, M
TERES, D
ARTIGAS, A
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (08): : 644 - 650
[6] LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2963
[7] An economic evaluation of activated protein C treatment for severe sepsis.
Manns, BJ
Lee, H
Doig, CJ
Johnson, D
Donaldson, C
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 993 - 1000
[8] Early goal-directed therapy in the treatment of severe sepsis and septic shock.
Rivers, E
Nguyen, B
Havstad, S
Ressler, J
Muzzin, A
Knoblich, B
Peterson, E
Tomlanovich, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) : 1368 - 1377
[9] Assessing the use of activated protein c in the treatment of severe sepsis.
Siegel, JP
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 1030 - 1034
[10] WHY SEVERITY MODELS SHOULD BE USED WITH CAUTION
TERES, D
LEMESHOW, S
[J]. CRITICAL CARE CLINICS, 1994, 10 (01) : 93 - 110

← 1 2 →